

Consolidated Financial Results for the Fiscal Year Ended April 30, 2026

[Under Japanese GAAP]

June 11, 2026

Name of listed company: **AIN HOLDINGS INC.**
Exchange listed on: Prime Market of Tokyo Stock Exchange and Sapporo Securities Exchange
Code number: 9627 URL: <https://www.ainj.co.jp/corporate/>
Representative: Kiichi Otani, President and Representative Director
Inquiries: Toshihide Mizushima, Representative Senior Managing Director
TEL: +81-3-5333-1812
Date of the ordinary general meeting of shareholders: July 30, 2026
Date of scheduled payment of dividends: July 31, 2026
Date of filing securities report: July 29, 2026
Supplementary documents for this summary of financial statements: Yes (Supplementary materials are disclosed on the Company's website appropriately as the financial statements.)
Explanation meeting for financial results: Yes (for institutional investors and analysts)

(Amounts are rounded down to the nearest million yen.)

1. Consolidated results for the fiscal year ended April 2026 (from May 1, 2025 to April 30, 2026)

(1) Consolidated operating results (Percentage figures show year-on-year changes.)

	Net sales		EBITDA		Operating profit		Ordinary profit		Profit attributable to owners of parent	
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Million yen	%
Year ended April 30, 2026	647,834	41.8	52,011	67.6	29,832	76.8	28,414	57.2	17,264	86.4
Year ended April 30, 2025	456,804	14.3	31,040	(0.9)	16,871	(17.4)	18,080	(15.4)	9,261	(18.8)

(Note) Comprehensive income: Year ended April 30, 2026: ¥19,031 million (98.0%)

Year ended April 30, 2025: ¥9,611 million (-18.4%)

(Note) EBITDA = operating profit + depreciation + amortization of goodwill

	Profit per share	Diluted profit per share	Return on equity	Ordinary profit to total assets	Operating profit to net sales
	Yen	Yen	%	%	%
Year ended April 30, 2026	491.62	—	11.5	6.9	4.6
Year ended April 30, 2025	264.32	—	6.7	6.4	3.7

(Reference) Equity in earnings of affiliates: Year ended April 30, 2026: ¥— million Year ended April 30, 2025: ¥— million

(2) Consolidated financial position

	Total assets	Net assets	Shareholders' equity ratio	Net assets per share
	Million yen	Million yen	%	Yen
As of April 30, 2026	509,647	159,171	31.2	4,523.45
As of April 30, 2025	311,921	142,632	45.7	4,063.53

(Reference) Equity capital: As of April 30, 2026: ¥158,998 million As of April 30, 2025: ¥142,520 million

(3) Consolidated cash flows

	Cash flows from operating activities	Cash flows from investing activities	Cash flows from financing activities	Cash and cash equivalents at end of year
	Million yen	Million yen	Million yen	Million yen
Year ended April 30, 2026	30,872	(60,605)	53,728	50,650
Year ended April 30, 2025	23,146	(65,920)	21,051	26,655

2. Dividends

	Dividends per share					Total dividends (annual)	Dividends payout ratio (consolidated)	Dividends on net assets (consolidated)
	1Q-end	2Q-end	3Q-end	Year-end	Annual			
	Yen	Yen	Yen	Yen	Yen	Million yen	%	%
Year ended April 30, 2025	—	0.00	—	80.00	80.00	2,826	30.3	2.0
Year ended April 30, 2026	—	0.00	—	100.00	100.00	3,533	20.3	2.3
Year ending April 30, 2027 (forecast)	—	0.00	—	100.00	100.00		23.4	

3. Consolidated financial forecast for the fiscal year ending April 30, 2027 (from May 1, 2026 to April 30, 2027)

(Percentage figures show year-on-year changes.)

	Net sales		EBITDA		Operating profit		Ordinary profit		Profit attributable to owners of parent		Earnings per share
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Yen
First half	351,600	17.3	25,100	23.2	12,600	19.8	11,250	13.5	5,700	26.8	162.16
Full year	721,500	11.4	58,110	11.7	32,500	8.9	30,000	5.6	15,000	(13.1)	426.74

* Notes

(1) Significant changes in the scope of consolidation during the period: Yes

Newly consolidated: 13 (AIN-AG1 Co., Ltd. and other 12) Excluded: —

(2) Changes in accounting principles, changes in accounting estimates, and restatement of revisions

- 1) Changes in accounting principles as a result of revisions to accounting standards, etc.: No
- 2) Changes in accounting principles other than 1): No
- 3) Changes in accounting estimates: No
- 4) Restatement of revisions: No

(3) Number of outstanding shares (common stock):

1) Number of outstanding shares (including treasury shares):	As of April 30, 2026	35,428,212 shares	As of April 30, 2025	35,428,212 shares
2) Number of shares held in treasury:	As of April 30, 2026	278,291 shares	As of April 30, 2025	354,987 shares
3) Average number of shares outstanding:	Fiscal year ended April 30, 2026	35,118,180 shares	Fiscal year ended April 30, 2025	35,037,809 shares

(Note) The number of treasury shares at the end of the fiscal year includes the Company's shares held by Custody Bank of Japan, Ltd. (Trust Account E) (as of April 30, 2025: 257,400 shares, as of April 30, 2026: 184,900 shares). In addition, the Company's shares held by Custody Bank of Japan, Ltd. (Trust Account E) are included in treasury shares deducted from the calculation of average number of shares outstanding during the period (fiscal year ended April 30, 2025: 291,975 shares, fiscal year ended April 30, 2026: 215,242 shares).

*This Summary of Financial Statements is outside the scope of audit procedures.

*Statement regarding the proper use of financial forecasts and other special remarks

(Caution concerning forward-looking statements)

The above forecasts are calculated based on the information available as of the publication date of this material, and actual financial results may vary due to change in future economic conditions and others.

Contents of Attachment

1. Operating Results and Other.....	2
(1) Overview of operating results for the fiscal year under review.....	2
(2) Overview of financial position for the fiscal year under review.....	4
(3) Overview of cash flows for the fiscal year under review.....	4
(4) Future outlook	5
2. Basic Stance on Selection of Accounting Standards.....	5
3. Consolidated Financial Statements and Major Notes.....	6
(1) Consolidated balance sheet.....	6
(2) Consolidated statement of income and comprehensive income.....	8
Consolidated statement of income.....	8
Consolidated statement of comprehensive income	10
(3) Consolidated statement of changes in net assets.....	11
(4) Consolidated statement of cash flows.....	13
(5) Notes to consolidated financial statements	15
(Notes on the premise of a going concern)	15
(Notes on changes in accounting policies).....	15
(Additional information).....	15
(Notes on segment information, etc.).....	16
(Notes on per-share information).....	20

1. Operating Results and Other

(1) Overview of operating results for the fiscal year under review

During the fiscal year under review (May 1, 2025 to April 30, 2026; fiscal 2026), the Japanese economy recovered gradually along with an improvement in the employment and income environment. However, conditions remain uncertain due to the impact of the situation in the Middle East, fluctuations in financial and capital markets, and other factors.

Against this backdrop, in March 2025, the AIN HOLDINGS Group (the Group) announced its medium-to-long-term vision, “Ambitious Goals 2034: A decade to promote innovation and strive for our challenging goal of a trillion yen in sales.” To ensure medium-to-long-term corporate growth even in a rapidly changing market environment, we have established business-specific visions and aim to achieve net sales of ¥1 trillion for the fiscal year ending April 2034.

In its sustainability management, in light of the announcement of the medium-to-long-term vision and changes in the external environment, the Group reviewed its materiality issues in December 2025. We re-examined a wide range of relevant international standards and guidelines, requests from ESG evaluation institutions, and social issues unique to Japan and our industry. In addition, regarding the identified issues, we reviewed them from two perspectives: their impact on the Group and the expectations and requests of stakeholders. We carried out this review while taking into consideration the issues’ alignment with our corporate philosophy and medium-to-long-term vision, as well as the opinions of employees, future generations, and experts. As a result, in addition to various revisions to the content of the previous materiality issues, to newly clarify the Group’s stance and initiatives, we positioned “employee growth and engagement” (which was previously included within the materiality issue of a “sound management base”) as a new, independent materiality issue. We will set major initiatives, KPIs, and challenging targets based on each revised materiality issue, and promote various initiatives toward the achievement of each KPI.

Going forward, the AIN Group will continue to work to be a company that “people welcome to their communities” by helping to solve various social issues through its business activities.

Results for fiscal year 2026 (May 1, 2025 to April 30, 2026) are as follows. In addition, during the current consolidated fiscal year, the improvement in profitability of Sakura Pharmacy Group after becoming part of the group exceeded expectations, and as a result, it became necessary to record additional deferred tax assets to reflect future tax benefits, which led to the recognition of approximately ¥4 billion in additional profit attributable to owners of the parent.

(Million yen)	Fiscal 2025	Fiscal 2026	Change	Change (%)
Net sales	456,804	647,834	191,029	41.8
Operating profit	16,871	29,832	12,961	76.8
Ordinary profit	18,080	28,414	10,333	57.2
Profit attributable to owners of parent	9,261	17,264	8,003	86.4

Results by segment are as follows.

	(Million yen)	Fiscal 2025	Fiscal 2026	Change	Change (%)
Dispensing pharmacy business	Sales	384,783	556,424	171,641	44.6
	Segment profit	24,286	35,760	11,474	47.2
Retail business	Sales	61,041	80,255	19,214	31.5
	Segment profit	4,804	6,528	1,724	35.9
Other businesses	Sales	11,034	11,523	488	4.4
	Segment profit	4	67	62	1,277.9

(Note) Segment sales include intersegment transactions.

(Dispensing pharmacy business)

In the dispensing pharmacy business, the Group’s vision is to “become the primary care pharmacy of choice for local communities, backed by proven expertise.” To realize this vision, the Group is working to leverage the

primary care capabilities of its pharmacists and dispensing pharmacies to help patients access medical services in their local community with peace of mind. Specifically, the Group is cooperating with medical institutions, using patient medication notebooks to ensure integrated and continuous monitoring of patient medication, and providing services for home-based healthcare.

We commenced sales of emergency contraceptives (the “morning-after pill”) at approximately 1,000 dispensing pharmacies nationwide in response to such contraceptives becoming available for sale as over-the-counter (OTC) drugs from February 2026. Since the earlier that emergency contraceptives are taken, the more effective they are, prompt response is important; however, they are also medications whose misuse needs to be prevented. Pharmacists who have completed the Group’s training will encourage correct usage of emergency contraceptives, and we will strive to provide support in collaboration with other healthcare professionals, including guidance on subsequent steps.

The Group is also actively promoting digital transformation to improve convenience for patients. This includes making its prescriptions sending service more accessible for patients by enabling access through the official AIN Pharmacy app, Anytime AIN Pharmacy and the official AIN Pharmacy LINE account. In June 2025, to further improve convenience, the Company added a “Mynportal Information” function to the official Anytime AIN Pharmacy app, which allows users to retrieve their medication information from Mynportal, the government’s online portal for administrative procedures. In addition, in November of the same year, the Company added an “Automatic Registration” function that automatically reflects information on medications received from AIN Pharmacy in the “Medication Notebook” within the app.

In addition to above measures, we are working to improve productivity by leveraging AI functions, such as introducing an “AI Medication History” to assist in documenting patient medication histories that chronologically record patient information and guidance for drug usage, and an “AI Diagnostic Report” that analyzes and identifies operational issues at our pharmacies.

During the fiscal year, the average prescription price rose due to an increase in high-cost prescriptions. The number of prescriptions also remained steady, reflecting higher service levels related to improvements in the capabilities of primary care pharmacists and pharmacies and reduced waiting times.

Furthermore, as announced on August 1, 2025, in the “Notice Regarding New Management Structure and Personnel Changes Following the Acquisition of Shares of Sakura Pharmacy Group,” (only Japanese version available) Sakura Pharmacy Group, which operates dispensing pharmacies primarily in densely populated areas such as the Tokyo metropolitan area, the Kansai area, and the Tokai region, has joined the Group. Going forward, by integrating our mutual business know-how and contributing to patients and local healthcare, we will increase the Group’s corporate value as an infrastructure for community healthcare nationwide.

During the period under review, the Group opened 902 new dispensing pharmacies, including those acquired through M&A deals, closed 30, and sold 25, resulting in a total of 2,137.

(Retail business)

In the retail business, the Group operates the chain of AINZ & TULPE cosmetics stores, which are clearly differentiated from other retailers with their unique product offerings centered on cosmetics and exclusive and advance sales of Asian cosmetics brands. In addition, Francfranc, a chain of lifestyle stores, carries out all planning, manufacturing and sale of furniture and homeware products on an integrated basis to offer comfortable daily lifestyle proposals with diverse designs and flexible styling.

During the fiscal year, at AINZ & TULPE, although results were affected by large store closures for renovations, the number of customers at stores opened in the previous fiscal year remained firm. In addition, unit prices increased due to continued growth in sales of Asian cosmetics from the previous fiscal year. At Francfranc, although results were affected by the temporary closure of two flagship stores for renovations, sales remained firm, supported by strong sales of the “Frais Handy Fan” series of portable fans due to last summer’s record-breaking heatwave, and by strong sales during the Christmas and back-to-school and new employment shopping seasons. On the other hand, we have identified key management issues for further business

expansion, and will strive to enhance corporate value by addressing them as priority measures for sustainable growth. Going forward, we will leverage the strengths of both AINZ & TULPE and Francfranc to generate synergies, as well as reinforce merchandise lineups and create attractive sales displays while closely monitoring buying trends. During the same period, the Group opened 14 AINZ & TULPE stores and closed three, resulting in a total of 106 stores. In addition, the Group opened seven Francfranc stores and closed nine, resulting in a total of 163 stores, with the number of stores in the retail business totaling 269 at the end of the period under review.

(2) Overview of financial position for the fiscal year under review

The balance of total assets at the end of the fiscal year increased ¥197,726 million from the end of the previous fiscal year to ¥509,647 million. The main factor was an increase in non-current assets, primarily goodwill, and accounts receivable - trade due to M&A deals, including the consolidation of Sakura Pharmacy Group.

The balance of liabilities increased ¥181,187 million to ¥350,476 million. The main factors were an increase in accounts payable - trade due to the consolidation of Sakura Pharmacy Group and funds procured from financial institutions for the acquisition of shares. As a result, the balance of short-term and long-term borrowings increased ¥133,232 million to ¥171,854 million.

Total net assets increased ¥16,539 million to ¥159,171 million and the shareholders' equity ratio declined 14.5 percentage points to 31.2%.

(3) Overview of cash flows for the fiscal year under review

In the fiscal year under review, cash and cash equivalents increased ¥23,995 million year on year to ¥50,650 million.

Cash flows from each category and their relevant factors are as follows.

(Cash flows from operating activities)

Net cash provided by operating activities was ¥30,872 million, compared with net cash provided of ¥23,146 million in the previous fiscal year.

The main items that were positive for cash flow were profit before income taxes of ¥24,047 million, as well as depreciation of ¥11,102 million, amortization of goodwill of ¥11,077 million, and increase (decrease) in trade payables of ¥4,791 million, related to business expansion through new store openings and M&A.

Income taxes paid of ¥8,816 million, increase in trade receivables of ¥3,929 million, and increase in inventories of ¥3,513 million were the main negative items for operating cash flow.

(Cash flows from investing activities)

Net cash used in investing activities was ¥60,605 million, compared with net cash used of ¥65,920 million in the previous fiscal year.

This mainly reflected cash used of ¥45,870 million for purchase of shares of subsidiaries resulting in change in scope of consolidation related to shares acquired in 20 companies through M&A deals, and ¥9,898 million for purchases of property, plant and equipment related to the opening of new stores of dispensing pharmacy business and retail business.

(Cash flows from financing activities)

Net cash provided by financing activities was ¥53,728 million, compared with net cash used of ¥21,051 million in the previous fiscal year.

The main items were net funds procured of ¥57,111 million from short-term and long-term borrowings, including the repayment of borrowings and bonds of Sakura Pharmacy Group upon joining the Group, and

dividends paid of ¥2,826 million.

Changes in the Group's cash flow indicators are shown below.

	Year ended April 30, 2023	Year ended April 30, 2024	Year ended April 30, 2025	Year ended April 30, 2026
Shareholders' equity ratio (%)	54.6	54.3	45.7	31.2
Shareholders' equity ratio based on market value (%)	85.5	83.8	62.1	38.9
Debt redemption term (years)	0.4	0.3	1.7	5.6
Interest coverage ratio (times)	384.8	588.1	91.8	14.3

Notes: Shareholders' equity ratio = Equity capital / total assets

Shareholders' equity ratio based on market value = market capitalization / total assets

Debt redemption term = interest-bearing debt / operating cash flows

Interest coverage ratio = operating cash flows / interest paid

*All indicators are calculated based on consolidated financial data.

*Interest-bearing debt includes all liabilities recorded on the balance sheet on which interest is being paid.

*Operating cash flows and interest paid are calculated using the cash flows from operating activities and the interest paid on the consolidated statements of cash flows.

(4) Future outlook

In the next fiscal year (May 1, 2026 to April 30, 2027; fiscal 2027), we will continue to expand the dispensing pharmacy business by developing new pharmacies and actively using M&A.

In the retail business, we will continue to open AINZ & TULPE and Francfranc stores in prime locations and create appealing retail displays by strengthening product lineups in order to attract more customers, while also continuing to improve operational efficiency.

However, we expect raw material and fuel prices to remain high and forecast sustained price inflation in various products categories. In addition, we plan to invest in IT systems to enhance the functionality of apps to improve customer service and to strengthen the management base. We will also invest in promoting human capital management. While costs are likely to increase due to these factors, we expect productivity improvements in the dispensing pharmacy business due to the progress in the PMI of Sakura Pharmacy Group, as well as earnings improvement at AINZ & TULPE and Francfranc through new store openings, cost reductions, etc., and we forecast higher net sales and ordinary profit.

Our forecasts for fiscal 2027 (May 1, 2026 to April 30, 2027) are as follows.

	Fiscal 2026 (Million yen)	Fiscal 2027 (Million yen)	Change (Million yen)	Change (%)
Net sales	647,834	721,500	73,665	11.4
Ordinary profit	28,414	30,000	1,585	5.6
Profit attributable to owners of parent	17,264	15,000	(2,264)*	(13.1)

* The amount is affected by the recording of deferred tax assets in the current consolidated fiscal year.

2. Basic Stance on Selection of Accounting Standards

The Group has adopted Japanese accounting standards in order to facilitate comparison with other domestic companies in the same sector. The Group plans to appropriately address the adoption of International Financial Reporting Standards (IFRS) while taking into account trends in Japan and overseas.

3. Consolidated Financial Statements and Major Notes

(1) Consolidated balance sheet

(Million yen)

	Fiscal year ended April 30, 2025 (As of April 30, 2025)	Fiscal year ended April 30, 2026 (As of April 30, 2026)
Assets		
Current assets		
Cash and deposits	26,881	50,925
Accounts receivable - trade	22,295	35,204
Merchandise	35,572	46,620
Supplies	499	910
Short-term loans receivable	348	52
Accounts receivable - other	20,611	26,333
Other	6,601	13,181
Allowance for doubtful accounts	(0)	(54)
Total current assets	112,808	173,173
Non-current assets		
Property, plant and equipment		
Buildings and structures	57,892	75,155
Accumulated depreciation	(26,243)	(36,759)
Buildings and structures, net	31,648	38,395
Land	10,218	14,283
Construction in progress	1,652	871
Other	19,495	26,244
Accumulated depreciation	(13,303)	(18,254)
Other, net	6,192	7,990
Total property, plant and equipment	49,712	61,541
Intangible assets		
Goodwill	84,772	194,182
Other	12,848	14,117
Total intangible assets	97,621	208,300
Investments and other assets		
Investment securities	3,233	4,652
Long-term loans receivable	665	578
Deferred tax assets	7,679	17,295
Retirement benefit asset	—	648
Leasehold and guarantee deposits	31,091	33,571
Other	9,357	10,025
Allowance for doubtful accounts	(249)	(140)
Total investments and other assets	51,778	66,632
Total non-current assets	199,112	336,474
Total assets	311,921	509,647

(Million yen)

	Fiscal year ended April 30, 2025 (As of April 30, 2025)	Fiscal year ended April 30, 2026 (As of April 30, 2026)
Liabilities		
Current liabilities		
Accounts payable - trade	80,895	113,874
Short-term borrowings	12,151	20,747
Income taxes payable	4,449	7,183
Deposits received	20,685	23,536
Provision for bonuses	4,167	6,098
Provision for bonuses for directors	23	19
Contract liabilities	534	600
Other	9,136	12,995
Total current liabilities	132,045	185,056
Non-current liabilities		
Long-term borrowings	26,469	151,106
Lease liabilities	105	30
Retirement benefit liability	4,778	5,313
Asset retirement obligations	4,081	6,438
Other	1,808	2,530
Total non-current liabilities	37,243	165,419
Total liabilities	169,288	350,476
Net assets		
Shareholders' equity		
Share capital	21,894	21,894
Capital surplus	20,128	20,004
Retained earnings	101,692	116,130
Treasury shares	(1,997)	(1,572)
Total shareholders' equity	141,717	156,457
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	298	965
Deferred gains or losses on hedges	189	329
Foreign currency translation adjustment	(3)	(3)
Remeasurements of defined benefit plans	318	1,250
Total accumulated other comprehensive loss	802	2,541
Non-controlling interests	111	172
Total net assets	142,632	159,171
Total liabilities and net assets	311,921	509,647

(2) Consolidated statement of income and comprehensive income**Consolidated statement of income**

(Million yen)

	Fiscal year ended April 30, 2025 (May 1, 2024 to April 30, 2025)	Fiscal year ended April 30, 2026 (May 1, 2025 to April 30, 2026)
Net sales	456,804	647,834
Cost of sales	382,368	538,956
Gross profit	74,436	108,878
Selling, general and administrative expenses		
Advertising expenses	2,517	2,863
Sales promotion costs	502	717
Salaries, allowances and bonuses	11,925	14,073
Provision for bonuses	1,552	2,151
Provision for bonuses for directors	23	19
Retirement benefit expenses	301	419
Legal and other welfare expenses	3,726	6,011
Communication and transportation expenses	1,582	2,292
Lease expenses	91	116
Rent expenses on land and buildings	8,654	11,498
Provision of allowance for doubtful accounts	—	74
Depreciation	3,041	4,188
Amortization of goodwill	5,796	11,077
Taxes and dues	3,174	4,426
Other	14,673	19,115
Total selling, general and administrative expenses	57,565	79,045
Operating profit	16,871	29,832
Non-operating income		
Interest income	49	169
Dividend income	36	49
Gain on investments in investment partnerships	20	54
Commission income	7	15
Rental income from real estate	346	319
Gain on receipt of donated non-current assets	30	28
Outsourcing service income	375	580
Technical advisory fee income	64	58
Subsidy income	630	316
Other	507	1,104
Total non-operating income	2,069	2,697
Non-operating expenses		
Interest expenses	264	2,093
Loss on sale of receivables	335	607
Rental expenses on real estate	163	664
Other	96	749
Total non-operating expenses	859	4,115
Ordinary profit	18,080	28,414

(Million yen)

	Fiscal year ended April 30, 2025 (May 1, 2024 to April 30, 2025)	Fiscal year ended April 30, 2026 (May 1, 2025 to April 30, 2026)
Extraordinary income		
Gain on sale of non-current assets	168	57
Gain on sale of businesses	561	174
Surrender value of insurance policies	15	22
Gain on bargain purchase	—	74
Other	72	32
Total extraordinary income	817	361
Extraordinary losses		
Loss on sale and retirement of non-current assets	206	527
Impairment losses	1,848	3,921
Loss on valuation of investment securities	43	172
Other	93	107
Total extraordinary losses	2,193	4,728
Profit before income taxes	16,705	24,047
Income taxes – current	8,280	11,260
Income taxes – deferred	(843)	(4,505)
Total income taxes	7,436	6,755
Profit	9,268	17,292
Profit attributable to non-controlling interests	7	27
Profit attributable to owners of parent	9,261	17,264

Consolidated statement of comprehensive income

(Million yen)

	Fiscal year ended April 30, 2025 (May 1, 2024 to April 30, 2025)	Fiscal year ended April 30, 2026 (May 1, 2025 to April 30, 2026)
Profit	9,268	17,292
Other comprehensive income		
Valuation difference on available-for-sale securities	63	667
Deferred gains or losses on hedges	189	139
Foreign currency translation adjustment	(3)	(0)
Remeasurements of defined benefit plans, net of tax	93	932
Total other comprehensive income	343	1,739
Comprehensive income	9,611	19,031
Comprehensive income attributable to owners of parent	9,604	19,003
Comprehensive income attributable to non-controlling interests	7	28

(3) Consolidated statement of changes in net assets

Fiscal 2025 (May 1, 2024 to April 30, 2025)

(Million yen)

	Shareholders' equity				
	Share capital	Capital surplus	Retained earnings	Treasury shares	Total shareholders' equity
Balance at the beginning of current year	21,894	20,131	95,257	(2,436)	134,847
Changes during period					
Dividends of surplus			(2,826)		(2,826)
Profit attributable to owners of parent			9,261		9,261
Purchase of treasury shares				(0)	(0)
Disposal of treasury shares		(2)		439	436
Net change in items other than shareholders' equity					
Total changes during period	–	(2)	6,435	438	6,870
Balance at the end of current year	21,894	20,128	101,692	(1,997)	141,717

	Accumulated other comprehensive income					Non-controlling interests	Total net assets
	Valuation difference on available-for-sale securities	Deferred gains or losses on hedges	Foreign currency translation adjustment	Remeasurements of defined benefit plans	Total accumulated other comprehensive income (loss)		
Balance at the beginning of current year	234	–	–	225	459	104	135,411
Changes during period							
Dividends of surplus							(2,826)
Profit attributable to owners of parent							9,261
Purchase of treasury shares							(0)
Disposal of treasury shares							436
Net change in items other than shareholders' equity	63	189	(3)	93	343	7	350
Total changes during period	63	189	(3)	93	343	7	7,220
Balance at the end of current year	298	189	(3)	318	802	111	142,632

Fiscal 2026 (May 1, 2025 to April 30, 2026)

(Million yen)

	Shareholders' equity				
	Share capital	Capital surplus	Retained earnings	Treasury shares	Total shareholders' equity
Balance at the beginning of current year	21,894	20,128	101,692	(1,997)	141,717
Changes during period					
Dividends of surplus			(2,826)		(2,826)
Profit attributable to owners of parent			17,264		17,264
Disposal of treasury shares		0		425	426
Change in ownership interest of parent due to transactions with non-controlling interests		(125)			(125)
Net change in items other than shareholders' equity					
Total changes during period	–	(124)	14,438	425	14,739
Balance at the end of current year	21,894	20,004	116,130	(1,572)	156,457

	Accumulated other comprehensive income					Non-controlling interests	Total net assets
	Valuation difference on available-for-sale securities	Deferred gains or losses on hedges	Foreign currency translation adjustment	Remeasurements of defined benefit plans	Total accumulated other comprehensive income (loss)		
Balance at the beginning of current year	298	189	(3)	318	802	111	142,632
Changes during period							
Dividends of surplus							(2,826)
Profit attributable to owners of parent							17,264
Disposal of treasury shares							426
Change in ownership interest of parent due to transactions with non-controlling interests							(125)
Net change in items other than shareholders' equity	666	139	(0)	932	1,738	61	1,799
Total changes during period	666	139	(0)	932	1,738	61	16,539
Balance at the end of current year	965	329	(3)	1,250	2,541	172	159,171

(4) Consolidated statement of cash flows

(Million yen)

	Fiscal year ended April 30, 2025 (May 1, 2024 to April 30, 2025)	Fiscal year ended April 30, 2026 (May 1, 2025 to April 30, 2026)
Cash flows from operating activities		
Profit before income taxes	16,705	24,047
Depreciation	8,372	11,102
Amortization of goodwill	5,796	11,077
Impairment losses	1,848	3,921
Increase (decrease) in allowance for doubtful accounts	(29)	(216)
Increase in retirement benefit liability	266	212
Increase in contract liabilities	68	66
Gain on sale of businesses	(561)	(166)
Increase in provision for bonuses	485	(663)
Decrease in provision for bonuses for directors	(6)	(4)
Interest and dividend income	(85)	(219)
Interest expenses	264	2,093
Gains on investments in partnerships	(11)	(48)
Gain on receipt of donated non-current assets	(30)	(28)
Gains on sale of investments securities	(70)	(27)
Loss on valuation of investment securities	43	172
Losses on sale and retirement of non-current assets	37	470
Decrease in trade receivables	(1,287)	(3,929)
(Increase) decrease in inventories	(3,807)	(3,513)
Increase in other assets	(1,121)	(4,768)
Increase in other accounts receivable - other	(4,275)	692
Increase (decrease) in trade payables	8,999	4,791
Increase (decrease) in other liabilities	727	(3,431)
Other, net	39	(48)
Subtotal	32,371	41,582
Interest and dividends received	85	273
Interest paid	(252)	(2,166)
Income taxes paid	(9,058)	(8,816)
Net cash provided by operating activities	23,146	30,872

(Million yen)

	Fiscal year ended April 30, 2025 (May 1, 2024 to April 30, 2025)	Fiscal year ended April 30, 2026 (May 1, 2025 to April 30, 2026)
Cash flows from investing activities		
Purchase of property, plant and equipment	(7,968)	(9,898)
Proceeds from sale of property, plant and equipment	1,201	856
Purchase of investment securities	(60)	(316)
Proceeds from sale of investment securities	458	178
Purchase of shares of subsidiaries resulting in change in scope of consolidation	(51,455)	(45,870)
Payments for loans receivable	(119)	(47)
Proceeds from collection of loans receivable	37	536
Purchase of intangible assets	(4,215)	(5,205)
Proceeds from sale of intangible assets	473	2
Payments of leasehold and guarantee deposits	(4,704)	(1,385)
Proceeds from refund of leasehold and guarantee deposits	1,914	2,278
Decrease (increase) in investments and other assets	(1,595)	(2,112)
Proceeds from withdrawal of time deposits	239	137
Payments into time deposits	(0)	(0)
Other, net	(126)	240
Net cash used in investing activities	(65,920)	(60,605)
Cash flows from financing activities		
Net decrease in short-term borrowings	5,462	(6,713)
Proceeds from long-term borrowings	32,100	150,939
Repayments of long-term borrowings	(13,535)	(75,933)
Redemption of bonds	—	(11,180)
Purchase of treasury shares	(0)	—
Proceeds from sale of treasury shares	422	400
Purchase of shares of subsidiaries not resulting in change in scope of consolidation	—	(455)
Dividends paid	(2,826)	(2,826)
Dividends paid to non-controlling interests	—	(200)
Other, net	(570)	(301)
Net cash provided by (used in) financing activities	21,051	53,728
Effect of exchange rate change on cash and cash equivalents	(3)	(0)
Net increase (decrease) in cash and cash equivalents	(21,725)	23,995
Cash and cash equivalents at beginning of the year	48,381	26,655
Cash and cash equivalents at end of the year	26,655	50,650

(5) Notes to consolidated financial statements

(Notes on the premise of a going concern)

There are no applicable matters to be reported.

(Notes on changes in accounting policies)

There are no applicable matters to be reported.

(Additional information)

(Transactions for delivering the Company's own shares to employees etc. through trusts)

The Company conducts transactions to deliver its own shares through a trust to an employee stock ownership plan to enhance the welfare of employees and provide incentives to increase the Company's corporate value.

1. Transaction summary

The Company has introduced the " Stock-Based Benefit Trust (Employee Shareholders Association Purchase Type) (the Plan) from April 2024.

With the introduction of the Plan, the Company, as the Trustor, entered into a Stock-Based Benefit Trust (Employee Shareholders Association Purchase Type) Agreement (the "Trust Agreement"; the trust established pursuant to the Trust Agreement is referred to as the "Trust") with Mizuho Trust & Banking Co., Ltd. (the "Trustee"). Additionally, the Trustee entered into a re-trust agreement with Custody Bank of Japan, Ltd. regarding the management of securities and other trust assets by Custody Bank of Japan, Ltd. as the subtrustee.

Custody Bank of Japan, Ltd. will make a single collective acquisition of the Company's shares in advance equivalent to the number of shares anticipated to be purchased by the AIN HOLDINGS Employee Shareholders Association (the "Shareholders Association") over the next five years, transferring them to the Trust E Account, and sell the Company's shares thereafter when purchases of the shares are made by the Shareholders Association. If an amount equivalent to the gains on sales of shares is accumulated in the trust assets of the Trust via the sale of the Company's shares up until the time of the Trust's termination, this cash shall be distributed as residual assets to the members of the Shareholders Association (employees) who satisfy the beneficiary eligibility requirements.

In addition, since the Company provides a guarantee when the Trustee takes out a loan in order for the Trust E Account to acquire the Company's shares, in a case in which the Trustee has an outstanding loan balance equal to the loss on the sale of shares as of the time of Trust's termination due to a drop in the Company's share price or other reasons, the Company will pay off the outstanding loan balance pursuant to the guarantee agreements.

2. Company's shares held in the trust

The Company's shares held in the trust are recorded as treasury shares under net assets at the acquisition cost (excluding the amount of incidental expenses). In the fiscal year ended April 30, 2025, the book value and number of these treasury shares amounted to ¥1,422 million and 257 thousand shares, respectively. And in the fiscal year ended April 30, 2026, the book value and number of these treasury shares amounted to ¥1,021 million and 184 thousand shares, respectively.

3. Book value of loans recorded under the gross amount method

Fiscal year ended April 30, 2025: ¥1,523 million

Fiscal year ended April 30, 2026: ¥1,092 million

(Notes on segment information, etc.)

Segment information

1. Description of the reportable segments

The Company's reportable segments consist of those of its components for which it is possible to obtain separate financial information that is examined by its Board of Directors on a regular basis for the purpose of deciding on the allocation of corporate resources and assessing business performance.

The Group's business comprises three units that together represent its main business units, namely, dispensing pharmacy business that consists of operation of dispensing pharmacies, selling of generic drugs, recruiting and consulting services, and retail business that consists of the management of cosmetics stores and lifestyle stores as well as other businesses, which includes a retail store business and a real-estate leasing business. The formulation and examination of business strategy is conducted individually for each business.

Based on the above, the Company has classified its business into three reportable segments – the dispensing pharmacy business, the retail business, and other businesses.

2. Methods to determine the amounts of net sales, profit or losses, assets, liabilities and other items by reportable segment

The methods used for accounting for the reportable business segments are generally similar to those described in the Basic Important Matters for Preparation of Consolidated Financial Statements.

The income figures for the reportable segments are expressed at the ordinary profit level.

Intersegment sales and transfers are based on prevailing market prices.

3. Sales, income (loss), assets, liabilities and other items for each reportable segment

I. Fiscal 2025 (May 1, 2024 to April 30, 2025)

(Million yen)

	Reportable segments				Adjustments (Note) 1	Consolidated (Note) 2
	Dispensing pharmacy business	Retail business	Other businesses	Total		
Sales						
Sales to third parties	384,783	61,041	10,979	456,804	—	456,804
Intersegment sales and transfers	—	—	54	54	(54)	—
Total sales	384,783	61,041	11,034	456,859	(54)	456,804
Segment profit (loss)	24,286	4,804	4	29,095	(11,014)	18,080
Segment assets	216,812	33,951	9,781	260,544	51,376	311,921
Other						
Depreciation	4,220	1,312	318	5,851	1,443	7,294
Amortization of goodwill	4,292	1,363	140	5,796	—	5,796
Impairment losses	1,572	211	21	1,805	43	1,848
Increase in property and equipment and intangible fixed assets	7,213	2,371	80	9,664	2,838	12,502

1. Segment profit (loss) in “Adjustments” totaling ¥(11,014) million includes ¥11,885 million in corporate expenses, ¥(804) million in (income) losses that may not be allocated to the reporting segments, and ¥(65) million in elimination due to intersegment transactions.

Corporate expenses consist mainly of expenses associated with the administrative divisions and the system logistics division of the parent company, which are not part of the reportable segments.

Segment assets in “Adjustments” totaling ¥51,376 million consist mainly of assets associated with the administrative divisions and the system logistics division of the parent company, which are not part of the reportable segments, and the difference in elimination of intersegment transactions.

Depreciation of ¥1,443 million, Impairment losses of ¥43 million, and increase in property and equipment and intangible fixed assets of ¥2,838 million in “Adjustments” for Other relate to assets under the control of the administrative divisions and the system logistics division of the parent company, which are not part of the reportable segments.

2. Segment profit (loss) is adjusted with the ordinary profit of consolidated statements of income.

II. Fiscal 2026 (May 1, 2025 to April 30, 2026)

(Million yen)

	Reportable segments				Adjustments (Note) 1	Consolidated (Note) 2
	Dispensing pharmacy business	Retail business	Other businesses	Total		
Sales						
Sales to third parties	556,424	80,255	11,153	647,834	—	647,834
Intersegment sales and transfers	—	—	369	369	(369)	—
Total sales	556,424	80,255	11,523	648,203	(369)	647,834
Segment profit (loss)	35,760	6,528	67	42,355	(13,941)	28,414
Segment assets	459,503	74,886	13,359	547,749	(38,101)	509,647
Other						
Depreciation	6,060	1,352	365	7,777	2,013	9,790
Amortization of goodwill	8,897	2,043	136	11,077	—	11,077
Impairment losses	3,223	180	493	3,898	23	3,921
Increase in property and equipment and intangible fixed assets	8,855	3,032	454	12,342	2,942	15,285

Notes: 1. Notes: 1. The adjustment of ¥(13,941) million to segment profit (loss) includes ¥13,844 million in corporate expenses, ¥(432) million in (income) loss that are not allocated to reportable segments, and ¥528 million in eliminations due to intersegment transactions.

Corporate expenses consist mainly of expenses associated with the administrative divisions and the system logistics division, which are not part of the reportable segments.

Segment assets in “Adjustments” totaling ¥(38,101) million consist mainly of assets associated with the administrative divisions and the system logistics division of the parent company, which are not part of the reportable segments, and the difference in elimination of intersegment transactions.

Depreciation of ¥2,013 million, impairment losses of ¥23 million, and increase in property and equipment and intangible fixed assets of ¥2,942 million in “Adjustments” under “Other” relate to assets under the control of the administrative divisions and the system logistics division of the parent company, which are not part of the reportable segments.

2. Segment profit (loss) is adjusted with the ordinary profit of consolidated statements of income.

Related information

Fiscal 2025 (May 1, 2024 to April 30, 2025)

1. Information by product and service

This disclosure has been omitted because the same information is disclosed under Segment information.

2. Information by region

(1) Net sales

This disclosure has been omitted as the Group's sales to external customers in Japan accounted for more than 90% of sales on the consolidated statement of income.

(2) Property, plant and equipment

This disclosure has been omitted as the Group's property, plant and equipment located in Japan accounted for more than 90% of property, plant and equipment on the consolidated balance sheet.

Fiscal 2026 (May 1, 2025 to April 30, 2026)

1. Information by product and service

This disclosure has been omitted because the same information is disclosed under Segment information.

2. Information by region

(1) Net sales

This disclosure has been omitted as the Group's sales to external customers in Japan accounted for more than 90% of sales on the consolidated statement of income.

(2) Property, plant and equipment

This disclosure has been omitted as the Group's property, plant and equipment located in Japan accounted for more than 90% of property, plant and equipment on the consolidated balance sheet.

Information regarding impairment losses of non-current assets for each reported segment

Fiscal 2025 (May 1, 2024 to April 30, 2025)

This disclosure has been omitted because the same information is disclosed under Segment information.

Fiscal 2026 (May 1, 2025 to April 30, 2026)

This disclosure has been omitted because the same information is disclosed under Segment information.

Information about amortization of goodwill amount and year-end unamortized balance for each reportable segment

Fiscal 2025 (May 1, 2024 to April 30, 2025)

(Million yen)

	Dispensing pharmacy business	Retail business	Other businesses	Corporate / Eliminations	Total
Amortization of fiscal year	4,292	1,363	140	—	5,796
Balance at the end of fiscal year	44,468	39,685	619	—	84,772

Fiscal 2026 (May 1, 2025 to April 30, 2026)

(Million yen)

	Dispensing pharmacy business	Retail business	Other businesses	Corporate / Eliminations	Total
Amortization of fiscal year	8,897	2,043	136	—	11,077
Balance at the end of fiscal year	156,522	37,641	18	—	194,182

Information about gains on bargain purchase for each reported segment

Fiscal 2025 (May 1, 2024 to April 30, 2025)

There are no applicable matters to be reported.

Fiscal 2026 (May 1, 2025 to April 30, 2026)

We have recognized a gain on bargain purchase for two newly consolidated subsidiaries in the dispensing pharmacy business. The recorded amount of the gain on bargain purchase resulting from this event is ¥74 million. Furthermore, as the gain on bargain purchase is recorded as extraordinary income, it is not included in the segment profit above.

(Notes on per-share information)

	Fiscal 2025 (May 1, 2024 to April 30, 2025)	Fiscal 2026 (May 1, 2025 to April 30, 2026)
Net assets per share	4,063.53 yen	4,523.45 yen
Earnings per share	264.32 yen	491.62 yen

Notes: 1. Diluted earnings per share is not mentioned since dilutive shares do not exist.

2. The Company's shares held by Custody Bank of Japan, Ltd. (Trust Account E) are included in treasury shares deducted from the total number of shares outstanding at the end of the fiscal year for the calculation of net assets per share (fiscal year ended April 30, 2025: 257 thousand shares, fiscal year ended April 30, 2026: 184 thousand shares). In addition, these shares are included in treasury shares deducted from the average number of shares outstanding during the period for the calculation of earnings per share (fiscal year ended April 30, 2025: 291 thousand shares, fiscal year ended April 30, 2026: 215 thousand shares).

3. The basis of calculation of net assets per share and earnings per share is as follows.

	Fiscal 2025 (May 1, 2024 to April 30, 2025)	Fiscal 2026 (May 1, 2025 to April 30, 2026)
Profit attributable to owners of parent (million yen)	9,261	17,264
Amount not attributable to ordinary shareholders (million yen)	—	—
Profit attributable to owners of the parent pertaining to common stock (million yen)	9,261	17,264
Average number of shares outstanding (shares)	35,037,809	35,118,180